GSK/Epix Alzheimer’s Drug Starts Phase IIb
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm tries again with PRX-03140/donepezil combo.
You may also be interested in...
Epix Gives Up GPCR Candidate To GSK For $5.5M
PRX-03140 for Alzheimer's is on track for second Phase IIb study this month, CEO tells "The Pink Sheet" DAILY.
Epix Gives Up GPCR Candidate To GSK For $5.5M
PRX-03140 for Alzheimer's is on track for second Phase IIb study this month, CEO tells "The Pink Sheet" DAILY.
Epix To Advance COPD, Alzheimer’s Drugs
Firm moving ahead after failed depression trial.